

Phase II trial of androgen deprivation therapy (ADT) and pembrolizumab for advanced stage androgen receptor-positive salivary gland carcinoma: Big Ten Cancer Research Consortium BTCRC-HN17-111

Status: Recruiting

Eligibility Criteria

Age: 18 years and over

This study is NOT accepting healthy

Healthy Volunteers: volunteers

Inclusion Criteria:

- at least 18 years old - locally advanced, recurrent, or metastatic salivary gland carcinoma that is not amenable to curative surgery or radiation - tumor is androgen receptor-positive - unable to do physically strenuous activity but can walk and is able to do work of a light nature, such as house work or office work - prior chemotherapy, radiation, or surgery as part of curative intent therapy are allowed - any number of prior lines of systemic therapy are permitted as long as it did not include anti-androgen therapy or immune checkpoint blockade - men and women of child bearing age must agree to use contraception during the treatment period and for at least 8 months after the last dose of study treatment - contact study staff for additional requirements

Exclusion Criteria:

- received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX40, CD137) - received prior androgen deprivation therapy - pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the first visit through 120 days after the last dose of trial treatment. - additional cancer that is progressing or has required active treatment within the past 2 years - contact study staff for additional exclusion criteria

Conditions & Interventions

Conditions:

Cancer

Keywords:

Salivary Gland Carcinoma, Clinics and Surgery Center (CSC)

More Information

Description: We are looking at the effectiveness of adding an immunotherapy drug, pembrolizumab, to usual treatment for people who have salivary gland cancer that can't be treated with surgery or radiation. The cancer must be androgen receptor positive.

Contact(s): Manish Patel - patel069@umn.edu

Principal Investigator: Manish Patel

IRB

Number: STUDY00004710

System ID: 20371

Thank you for choosing StudyFinder. Please visit <http://studyfinderstaging.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.